"Mycobacterium kansasii" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A slow-growing, photochromogenic species that is the etiologic agent of a tuberculosis-like disease in humans and is frequently isolated from human pulmonary secretions or tubercles. The incidence of infection is sharply increased among immunocompromised individuals. (Dorland, 28th ed)
| Descriptor ID |
D019909
|
| MeSH Number(s) |
B03.510.024.049.525.500.720.400 B03.510.460.400.410.552.552.720.400
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Mycobacterium kansasii".
Below are MeSH descriptors whose meaning is more specific than "Mycobacterium kansasii".
This graph shows the total number of publications written about "Mycobacterium kansasii" by people in this website by year, and whether "Mycobacterium kansasii" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 1 | 1 |
| 2020 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Mycobacterium kansasii" by people in Profiles.
-
Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ, Andrejak C, B?ttger EC, Brozek J, Griffith DE, Guglielmetti L, Huitt GA, Knight SL, Leitman P, Marras TK, Olivier KN, Santin M, Stout JE, Tortoli E, van Ingen J, Wagner D, Winthrop KL. Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. Clin Infect Dis. 2020 08 14; 71(4):e1-e36.
-
Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ, Andrejak C, B?ttger EC, Brozek J, Griffith DE, Guglielmetti L, Huitt GA, Knight SL, Leitman P, Marras TK, Olivier KN, Santin M, Stout JE, Tortoli E, van Ingen J, Wagner D, Winthrop KL. Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. Clin Infect Dis. 2020 08 14; 71(4):905-913.
-
Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ, Andrejak C, B?ttger EC, Brozek J, Griffith DE, Guglielmetti L, Huitt GA, Knight SL, Leitman P, Marras TK, Olivier KN, Santin M, Stout JE, Tortoli E, van Ingen J, Wagner D, Winthrop KL. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J. 2020 07; 56(1).
-
Molina-Torres CA, Ocampo-Candiani J, Rend?n A, Pucci MJ, Vera-Cabrera L. In vitro activity of a new isothiazoloquinolone, ACH-702, against Mycobacterium tuberculosis and other mycobacteria. Antimicrob Agents Chemother. 2010 May; 54(5):2188-90.